Navigation Links
TREVENTIS Corporation Founder Wins Prestigious Discovery Award
Date:1/11/2011

PHILADELPHIA and Nova Scotia, CANADA, Jan. 11, 2011 /PRNewswire/ -- TREVENTIS Corporation founder, Christopher Barden, Ph.D., was awarded "Emerging Professional Award" for his work in computer-aided drug design.  Dr. Barden received the Award at the 8th annual Discovery Awards dinner sponsored by Nova Scotia's Discovery Centre.  His work has provided TREVENTIS with a proprietary drug discovery system called the Common Conformational Motif (CCM).  

In addition, Company founder Sultan Darvesh, M.D., Ph.D., was one of only three finalists in the category of "Professional of Distinction" for his work and recognized expertise in the field of butyrylcholinesterase (BuChE) as a diagnostic and therapeutic target in diseases of the brain.  Dr. Darvesh heads the Company's efforts in developing a diagnostic test for Alzheimer's disease.  

Finalists and award winners are recognized by the Discovery Centre as the top science practitioners in Nova Scotia.  Three finalists are selected among all of Nova Scotia's scientific professionals in both the regular Professional and early-career Emerging categories.  The Discovery Awards "recognize the talented individuals...whose exemplary work in science and technology inspire us all," according to its web site (www.discoverycentre.ns.ca).  Past recipients of the Discovery Award include TREVENTIS founder Donald Weaver, M.D., Ph.D., a neurologist and recognized expert in Alzheimer's disease.

"We are delighted to have the scientific foundation of the Company validated by this prestigious award," said Bill McIntosh, CEO of TREVENTIS Corporation.  "That they were nominated for these awards is clear recognition of the significant work they are doing for the Company and for science."

Dr. Barden is part of a team of TREVENTIS chemists and biologists who have discovered and synthesized multiple classes of therapeutic compounds that block the aggregation of misfolding proteins.  Misfolding proteins have been implicated in numerous CNS diseases including Parkinson's disease and Alzheimer's disease, the Company's current focus.  

About TREVENTIS Corporation

TREVENTIS Corporation, headquartered in Southeastern Pennsylvania, has research operations in Halifax, Nova Scotia, Canada.  The company is focused on the discovery and early stage development of disease-modifying, small molecule drugs for Alzheimer's and other protein misfolding diseases such as Parkinson's and Huntington's disease.  In addition to its therapeutics programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis as well as monitoring treatment effects in Alzheimer's disease, MS and primary brain tumors.For more information contact:

L. William McIntosh, CEOTREVENTIS Corporationwww.TREVENTIS. commcamci@msn.com and wmcintosh@treventis.com610-488-6081  
'/>"/>

SOURCE TREVENTIS Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Saints Medical Center and ZOLL Medical Corporation Enter Collaborative Agreement
2. Luminex Corporation to Present at JP Morgan Healthcare Conference
3. SRI International Completes Integration of Sarnoff Corporation
4. Heska Corporation Announces Stockholder Approval of Reverse Split
5. Pfizer Animal Health to Acquire Synbiotics Corporation, Entering Diagnostics Sector
6. Webcast Alert: Heska Corporations Special Meeting of Stockholders Webcast
7. LodgeNet Healthcare, MDM Healthcare and Child Health Corporation of America Reach Agreement
8. VIDEO from Siemens Corporation Available on thenewsmarket.com: Amazing Medical Images: Diagnosing in the Digital Age
9. Heska Corporation Awards $25,000 Grand Prize to Pets Forever
10. Unilife Corporation Moves into New State-of-the-Art Manufacturing Facility and Global Headquarters
11. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 5, 2016 /PRNewswire/ ... announced the addition of the  "Europe ... - 2016"  report to their offering.  ... ) , ,The latest research ... Highlights - 2016, provides comprehensive insights ...
(Date:5/4/2016)... Holdings (NYSE: CODI ) ("CODI," "we," "our" ... businesses, announced today its consolidated operating results for the ... Quarter 2016 Highlights , Generated Cash Flow Available ... $13.6 million for the first quarter of 2016; ... first quarter of 2016; , Paid a first ...
(Date:5/4/2016)... , May 4, 2016 BiondVax ... CEO, Dr. Ron Babecoff , will be attending the ... City . On Thursday, May 5, Dr. ... conference presented by Joseph Gunner & Co, taking ... BiondVax presentation that Dr. Babecoff will be using is downloadable ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... If you don’t mind a ... your skin, you may want to consider a treatment that some have called the ... Dermatology P.C. , Microneedling, also known as skin needling, is a procedure using ...
(Date:5/5/2016)... Harbor City, NJ (PRWEB) , ... May 05, ... ... MAP Recovery Network Behavioral Health Population Management Platform, announced today that Enlightened Solutions ... will have the ability to optimize the care continuum for their patients being ...
(Date:5/5/2016)... ... May 05, 2016 , ... Nepenthe Laboratory Services (NLS), a premier drug ... to raise non-perishable food item donations for Food for Lane County, and to help ... , “The goal of the assembly was to create an exciting atmosphere for the ...
(Date:5/5/2016)... ... 05, 2016 , ... In an effort to increase public ... health promotion and research organization, declared May as “National Sunshine Month.” , ... in cultural behavior over the past several decades, Americans spend more time indoors ...
(Date:5/4/2016)... Viejo, CA (PRWEB) , ... May 04, 2016 , ... ... Final Cut Pro X . With ProList, editors can easily create lists ... stack presets to create additional bullet points. ProList is the perfect complement to ...
Breaking Medicine News(10 mins):